PRO-105, a phase II open-label study of NUC-1031 in patients with platinum-resistant ovarian cancer.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.tps5612
Abstract: TPS5612Background: Patients with platinum-resistant ovarian cancer, following ≥3 lines of chemotherapy have limited treatment options. NUC-1031, a phosphoramidate transformation of gemcitabine, is ... read more here.
Keywords: resistant ovarian; nuc 1031; ovarian cancer; platinum resistant ... See more keywords
REJOICE-Ovarian01: A phase 2/3 study of raludotatug deruxtecan (R-DXd) in patients with platinum-resistant ovarian cancer (OVC).
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.16_suppl.tps5625
Abstract: TPS5625 Background: Platinum resistance develops in most patients with OVC. Prognosis is poor and therapeutic options are limited, illustrating the significant unmet need in these patients. R-DXd is an antibody–drug conjugate comprising a humanized immunoglobulin… read more here.
Keywords: phase study; dxd; ovc; patients platinum ... See more keywords
Impact of Bevacizumab on Clinical Outcomes in Patients With Platinum-resistant Relapsed Ovarian Cancer
Sign Up to like & getrecommendations! Published in 2024 at "In Vivo"
DOI: 10.21873/invivo.13574
Abstract: Background/Aim: Over the past several decades, new anti-cancer drugs have been developed for the treatment of epithelial ovarian cancer. The development of drugs has led to changes in improving the prognosis of ovarian cancer patients.… read more here.
Keywords: cancer; platinum resistant; group; ovarian cancer ... See more keywords
Role of BRCA Mutation and HE4 in Predicting Chemotherapy Response in Ovarian Cancer: A Retrospective Pilot Study
Sign Up to like & getrecommendations! Published in 2021 at "Biomedicines"
DOI: 10.3390/biomedicines9010055
Abstract: Even though 80% of patients with High-Grade Serous Ovarian Cancer respond to standard first-line chemotherapy, a majority of them could relapse in the following five years due to a resistance to platinum. Human Epididymis protein… read more here.
Keywords: ovarian cancer; platinum resistant; patients platinum; brca ... See more keywords
Efficacy and safety of combined anlotinib-oral etoposide treatment for patients with platinum-resistant ovarian cancer
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Gynecologic Oncology"
DOI: 10.3802/jgo.2024.35.e100
Abstract: Objective Despite the availability of numerous treatment options, managing patients with platinum-resistant ovarian cancer (PROC) remains challenging, and the prognosis of PROC is notably unfavorable. This retrospective study aimed to assess the efficacy and safety… read more here.
Keywords: treatment; platinum resistant; ovarian cancer; resistant ovarian ... See more keywords
Niraparib in Japanese patients with platinum-sensitive recurrent ovarian cancer: final results of a multicenter phase 2 study
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Gynecologic Oncology"
DOI: 10.3802/jgo.2024.35.e115
Abstract: Objective This study evaluated the long-term safety and efficacy of niraparib in Japanese patients with platinum-sensitive recurrent ovarian cancer. Methods This was a follow-up analysis of a phase 2, multicenter, open-label, single-arm study in Japanese… read more here.
Keywords: japanese patients; ovarian cancer; patients platinum; study ... See more keywords